[{"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-001", "question": "A 52-year-old male presents with severe chronic watery diarrhea and 15 kg weight loss over 6 months. He has a history of hypertension treated with olmesartan and amlodipine. Celiac serologies (tTG-IgA, EMA) are negative. Upper endoscopy reveals scalloping of duodenal folds; biopsy shows total villous atrophy and increased intraepithelial lymphocytes. HLA-DQ2 and HLA-DQ8 genotyping is negative. A gluten-free diet for 8 weeks yields no clinical improvement. What is the most likely diagnosis?", "options": ["Refractory Celiac Disease Type 1", "Autoimmune Enteropathy", "Olmesartan-associated Enteropathy", "Common Variable Immunodeficiency (CVID)", "Tropical Sprue"], "answer": "C", "answer_index": 2, "explanation": "Olmesartan-associated enteropathy mimics celiac disease histologically (villous atrophy) but occurs in patients without the genetic predisposition for celiac disease (HLA-DQ2/DQ8 negative). The key discriminator is the medication history and lack of response to gluten withdrawal. Refractory celiac disease requires a prior confirmed diagnosis of celiac disease (positive genetics/serology).", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem provides discriminating clues: (1) celiac-like presentation with villous atrophy and scalloping, (2) negative celiac serologies (tTG-IgA, EMA), (3) negative HLA-DQ2/DQ8 (excludes genetic predisposition for celiac), (4) olmesartan use, and (5) no response to 8-week gluten-free diet. These findings strongly point to olmesartan-associated enteropathy, a well-documented drug-induced enteropathy that mimics celiac disease histologically but occurs without celiac genetics and fails to respond to gluten withdrawal. Option A (Refractory Celiac Type 1) requires prior confirmed celiac disease with positive genetics/serology, which this patient lacks. Option B (Autoimmune Enteropathy) is rare in adults and typically presents with anti-enterocyte antibodies. Option D (CVID) would show hypogammaglobulinemia and recurrent infections. Option E (Tropical Sprue) requires tropical exposure history not mentioned. The keyed answer C is uniquely defensible based on the medication history and negative celiac markers. Medical accuracy: The item correctly describes olmesartan-associated enteropathy's key features and appropriate differential diagnosis. No fix needed; item is logically valid and medically accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem provides discriminating clues: (1) celiac-like presentation with villous atrophy and scalloping, (2) negative celiac serologies (tTG-IgA, EMA), (3) negative HLA-DQ2/DQ8 (excludes genetic predisposition for celiac), (4) olmesartan use, and (5) no response to 8-week gluten-free diet. These findings strongly point to olmesartan-associated enteropathy, a well-documented drug-induced enteropathy that mimics celiac disease histologically but occurs without celiac genetics and fails to respond to gluten withdrawal. Option A (Refractory Celiac Type 1) requires prior confirmed celiac disease with positive genetics/serology, which this patient lacks. Option B (Autoimmune Enteropathy) is rare in adults and typically presents with anti-enterocyte antibodies. Option D (CVID) would show hypogammaglobulinemia and recurrent infections. Option E (Tropical Sprue) requires tropical exposure history not mentioned. The keyed answer C is uniquely defensible based on the medication history and negative celiac markers. Medical accuracy: The item correctly describes olmesartan-associated enteropathy's key features and appropriate differential diagnosis. No fix needed; item is logically valid and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-002", "question": "A 34-year-old female with a history of oral contraceptive use presents with right upper quadrant pain. MRI of the liver reveals a 6 cm solitary lesion in segment V. The lesion is hyperintense on T2-weighted images, shows strong arterial enhancement, and retains contrast on the hepatobiliary phase of Eovist (gadoxetate) MRI. Biopsy shows hepatocytes with glutamine synthetase diffuse strong positivity. What is the most appropriate management?", "options": ["Discontinue oral contraceptives and surveillance imaging in 6 months", "Surgical resection", "Radiofrequency ablation", "Liver transplantation evaluation", "Reassurance and discharge"], "answer": "B", "answer_index": 1, "explanation": "The imaging and staining pattern (diffuse glutamine synthetase positivity) are diagnostic of a beta-catenin activated hepatocellular adenoma. Unlike HNF1A-inactivated or inflammatory adenomas, beta-catenin activated adenomas have a very high risk of malignant transformation to hepatocellular carcinoma (HCC) and do not regress significantly with OCP cessation. Resection is mandated regardless of size or symptoms.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 34-year-old woman on OCPs with a 6 cm liver lesion showing characteristic imaging features (T2 hyperintense, arterial enhancement, hepatobiliary phase retention on Eovist) and diffuse strong glutamine synthetase positivity on biopsy—pathognomonic for beta-catenin activated hepatocellular adenoma (HCA). Key discriminating findings: (1) diffuse GS positivity distinguishes beta-catenin subtype from other HCA subtypes, (2) size >5 cm, (3) beta-catenin activation confers high malignant transformation risk to HCC (10-15%). The keyed answer (B, surgical resection) is correct because beta-catenin activated HCAs require resection regardless of size due to malignancy risk, unlike HNF1A-inactivated or inflammatory subtypes where OCP cessation and surveillance may suffice for smaller lesions. Alternative assessment: (A) inappropriate—beta-catenin HCAs don't regress with OCP cessation and carry transformation risk; (C) RFA inadequate for 6 cm lesion and doesn't provide tissue for margin assessment; (D) transplant not indicated for benign tumor amenable to resection; (E) dangerous given malignancy potential. No logical flaws; stem provides sufficient detail for unique best answer. Medical accuracy excellent—aligns with current hepatobiliary guidelines on HCA subtype management. Minimal fix: none needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 34-year-old woman on OCPs with a 6 cm liver lesion showing characteristic imaging features (T2 hyperintense, arterial enhancement, hepatobiliary phase retention on Eovist) and diffuse strong glutamine synthetase positivity on biopsy—pathognomonic for beta-catenin activated hepatocellular adenoma (HCA). Key discriminating findings: (1) diffuse GS positivity distinguishes beta-catenin subtype from other HCA subtypes, (2) size >5 cm, (3) beta-catenin activation confers high malignant transformation risk to HCC (10-15%). The keyed answer (B, surgical resection) is correct because beta-catenin activated HCAs require resection regardless of size due to malignancy risk, unlike HNF1A-inactivated or inflammatory subtypes where OCP cessation and surveillance may suffice for smaller lesions. Alternative assessment: (A) inappropriate—beta-catenin HCAs don't regress with OCP cessation and carry transformation risk; (C) RFA inadequate for 6 cm lesion and doesn't provide tissue for margin assessment; (D) transplant not indicated for benign tumor amenable to resection; (E) dangerous given malignancy potential. No logical flaws; stem provides sufficient detail for unique best answer. Medical accuracy excellent—aligns with current hepatobiliary guidelines on HCA subtype management. Minimal fix: none needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-003", "question": "A 24-year-old female presents with menorrhagia and prolonged bleeding after a tooth extraction. Coagulation profile shows a prolonged aPTT (55s) and normal PT. Factor VIII activity is 6% (low). von Willebrand Factor (vWF) Antigen is 95% (normal), and vWF Ristocetin Cofactor Activity is 92% (normal). A mixing study corrects the aPTT. Her father has a similar bleeding history, but her brothers are unaffected. What is the most likely diagnosis?", "options": ["Hemophilia A (Carrier state)", "Type 2N von Willebrand Disease", "Type 2A von Willebrand Disease", "Acquired Hemophilia A", "Factor XI Deficiency"], "answer": "B", "answer_index": 1, "explanation": "Type 2N (Normandy) vWD is caused by a defect in the vWF binding domain for Factor VIII, leading to a secondary deficiency of Factor VIII (due to short half-life) despite normal vWF levels and function. It mimics Hemophilia A but exhibits autosomal recessive inheritance (affecting females significantly), whereas Hemophilia A is X-linked. The normal vWF antigen and activity rule out Type 1 and 2A/2B/2M.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: The keyed answer (Type 2N vWD) is incorrect; the correct best answer is A (Hemophilia A carrier state). Key stem clues: 24-year-old female with menorrhagia and prolonged bleeding, prolonged aPTT (55s), normal PT, Factor VIII 6%, normal vWF antigen (95%) and ristocetin cofactor (92%), mixing study corrects aPTT, father affected, brothers unaffected. The family pattern (affected father, unaffected brothers, symptomatic daughter) is pathognomonic for X-linked recessive inheritance with the patient being a carrier. Type 2N vWD is autosomal recessive and would require both parents to be carriers; an affected father would have sons who are obligate carriers (unaffected) and daughters who are obligate carriers. The stem states brothers are unaffected, which fits X-linked but contradicts autosomal recessive where siblings would have 25% disease risk regardless of sex. A female Hemophilia A carrier with 6% Factor VIII (extreme lyonization) explains all findings including bleeding symptoms. Main logical issue: The keyed answer contradicts the inheritance pattern described. Main medical accuracy issue: The rationale incorrectly states Type 2N 'affects females significantly' and misrepresents its inheritance. Minimal fix: Change key to A or modify family history to show maternal inheritance pattern consistent with autosomal recessive disease.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: The keyed answer (Type 2N vWD) is incorrect; the correct best answer is A (Hemophilia A carrier state). Key stem clues: 24-year-old female with menorrhagia and prolonged bleeding, prolonged aPTT (55s), normal PT, Factor VIII 6%, normal vWF antigen (95%) and ristocetin cofactor (92%), mixing study corrects aPTT, father affected, brothers unaffected. The family pattern (affected father, unaffected brothers, symptomatic daughter) is pathognomonic for X-linked recessive inheritance with the patient being a carrier. Type 2N vWD is autosomal recessive and would require both parents to be carriers; an affected father would have sons who are obligate carriers (unaffected) and daughters who are obligate carriers. The stem states brothers are unaffected, which fits X-linked but contradicts autosomal recessive where siblings would have 25% disease risk regardless of sex. A female Hemophilia A carrier with 6% Factor VIII (extreme lyonization) explains all findings including bleeding symptoms. Main logical issue: The keyed answer contradicts the inheritance pattern described. Main medical accuracy issue: The rationale incorrectly states Type 2N 'affects females significantly' and misrepresents its inheritance. Minimal fix: Change key to A or modify family history to show maternal inheritance pattern consistent with autosomal recessive disease.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-004", "question": "A 19-year-old male presents with recurrent fevers, livedo reticularis, and two episodes of lacunar ischemic stroke. Laboratory evaluation reveals low serum IgM and IgG levels, mild neutropenia, and elevated inflammatory markers. A biopsy of a skin nodule shows necrotizing vasculitis. Genetic testing is most likely to reveal a loss-of-function mutation in which gene?", "options": ["MEFV", "ADA2", "NOD2", "TNFRSF1A", "STAT3"], "answer": "B", "answer_index": 1, "explanation": "This clinical presentation is classic for Deficiency of Adenosine Deaminase 2 (DADA2). It presents with a polyarteritis nodosa (PAN)-like vasculitis, early-onset strokes, and mild immunodeficiency (hypogammaglobulinemia/cytopenias). It is an autosomal recessive autoinflammatory disease. MEFV causes Familial Mediterranean Fever; STAT3 causes Hyper-IgE syndrome.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The stem describes a 19-year-old male with recurrent fevers, livedo reticularis, lacunar strokes, hypogammaglobulinemia (low IgM/IgG), mild neutropenia, elevated inflammatory markers, and necrotizing vasculitis on biopsy. Key discriminating findings are: (1) early-onset strokes in a young patient, (2) PAN-like vasculitis with livedo reticularis and necrotizing vasculitis, (3) immunodeficiency pattern (hypogammaglobulinemia and neutropenia), and (4) systemic inflammation. This constellation is pathognomonic for Deficiency of Adenosine Deaminase 2 (DADA2), caused by loss-of-function mutations in ADA2. The keyed answer B (ADA2) is correct. Alternative assessment: A (MEFV/FMF) presents with recurrent serositis and fever but not strokes or vasculitis; C (NOD2/Blau syndrome) causes granulomatous disease; D (TNFRSF1A/TRAPS) causes periodic fever without strokes or significant vasculitis; E (STAT3) causes Hyper-IgE syndrome with elevated IgE, eczema, and recurrent infections, not strokes or low immunoglobulins. The item is logically valid with a unique best answer matching the key. Medical accuracy is excellent; DADA2 is well-established with this classic triad of vasculitis, strokes, and immunodeficiency. No fix needed.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 19-year-old male with recurrent fevers, livedo reticularis, lacunar strokes, hypogammaglobulinemia (low IgM/IgG), mild neutropenia, elevated inflammatory markers, and necrotizing vasculitis on biopsy. Key discriminating findings are: (1) early-onset strokes in a young patient, (2) PAN-like vasculitis with livedo reticularis and necrotizing vasculitis, (3) immunodeficiency pattern (hypogammaglobulinemia and neutropenia), and (4) systemic inflammation. This constellation is pathognomonic for Deficiency of Adenosine Deaminase 2 (DADA2), caused by loss-of-function mutations in ADA2. The keyed answer B (ADA2) is correct. Alternative assessment: A (MEFV/FMF) presents with recurrent serositis and fever but not strokes or vasculitis; C (NOD2/Blau syndrome) causes granulomatous disease; D (TNFRSF1A/TRAPS) causes periodic fever without strokes or significant vasculitis; E (STAT3) causes Hyper-IgE syndrome with elevated IgE, eczema, and recurrent infections, not strokes or low immunoglobulins. The item is logically valid with a unique best answer matching the key. Medical accuracy is excellent; DADA2 is well-established with this classic triad of vasculitis, strokes, and immunodeficiency. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-005", "question": "A 65-year-old male with metastatic colorectal cancer is being evaluated for third-line therapy. Molecular profiling reveals the tumor is KRAS wild-type, NRAS wild-type, and BRAF V600E mutated. Microsatellite status is stable (MSS). Which of the following regimens is the most appropriate targeted therapy?", "options": ["Vemurafenib monotherapy", "Encorafenib plus Cetuximab", "Dabrafenib plus Trametinib", "Pembrolizumab monotherapy", "Regorafenib monotherapy"], "answer": "B", "answer_index": 1, "explanation": "In BRAF V600E-mutated colorectal cancer, BRAF inhibitor monotherapy (e.g., Vemurafenib) is ineffective due to a feedback loop that causes rapid upregulation of EGFR signaling. The standard of care, based on the BEACON trial, is the combination of a BRAF inhibitor (Encorafenib) and an EGFR inhibitor (Cetuximab) to block this feedback loop. Pembrolizumab is only for MSI-High tumors.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 65-year-old male with metastatic colorectal cancer (mCRC), BRAF V600E mutated, RAS wild-type, and MSS, requiring third-line therapy. Key discriminating findings: BRAF V600E mutation with RAS wild-type status makes the tumor eligible for BRAF-targeted therapy; MSS status excludes immune checkpoint inhibitors. The question tests knowledge of BRAF-mutated mCRC management. Option B (Encorafenib plus Cetuximab) is correct per BEACON CRC trial data showing superior outcomes with BRAF inhibitor plus EGFR inhibitor combination, which overcomes feedback EGFR upregulation seen with BRAF inhibitor monotherapy. Option A (Vemurafenib monotherapy) is ineffective due to paradoxical MAPK pathway reactivation. Option C (Dabrafenib plus Trametinib) shows activity in melanoma but inferior to BRAF+EGFR inhibition in mCRC. Option D (Pembrolizumab) requires MSI-H/dMMR status, explicitly excluded here (MSS). Option E (Regorafenib) is a multi-kinase inhibitor for refractory mCRC but not targeted therapy for BRAF mutation. The stem provides sufficient molecular details to identify a unique best answer. Medical accuracy is excellent, reflecting current NCCN/ASCO guidelines and landmark trial evidence. No fix needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 65-year-old male with metastatic colorectal cancer (mCRC), BRAF V600E mutated, RAS wild-type, and MSS, requiring third-line therapy. Key discriminating findings: BRAF V600E mutation with RAS wild-type status makes the tumor eligible for BRAF-targeted therapy; MSS status excludes immune checkpoint inhibitors. The question tests knowledge of BRAF-mutated mCRC management. Option B (Encorafenib plus Cetuximab) is correct per BEACON CRC trial data showing superior outcomes with BRAF inhibitor plus EGFR inhibitor combination, which overcomes feedback EGFR upregulation seen with BRAF inhibitor monotherapy. Option A (Vemurafenib monotherapy) is ineffective due to paradoxical MAPK pathway reactivation. Option C (Dabrafenib plus Trametinib) shows activity in melanoma but inferior to BRAF+EGFR inhibition in mCRC. Option D (Pembrolizumab) requires MSI-H/dMMR status, explicitly excluded here (MSS). Option E (Regorafenib) is a multi-kinase inhibitor for refractory mCRC but not targeted therapy for BRAF mutation. The stem provides sufficient molecular details to identify a unique best answer. Medical accuracy is excellent, reflecting current NCCN/ASCO guidelines and landmark trial evidence. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-006", "question": "A 45-year-old male presents with recurrent episodes of hypotension and syncope occurring 3 to 6 hours after eating dinner. He has no history of atopy. Skin prick tests to beef, pork, and lamb are negative, but intradermal testing is positive. Serum tryptase is normal. Specific IgE testing reveals elevated IgE to galactose-alpha-1,3-galactose. Which of the following is the most likely vector for sensitization in this patient?", "options": ["Ixodes scapularis (Black-legged tick)", "Amblyomma americanum (Lone Star tick)", "Dermacentor variabilis (American Dog tick)", "Aedes aegypti (Mosquito)", "Ctenocephalides felis (Cat flea)"], "answer": "B", "answer_index": 1, "explanation": "This is Alpha-gal syndrome, a delayed anaphylactic reaction to mammalian meat (red meat) mediated by IgE against the alpha-gal carbohydrate. Sensitization is caused by bites from the Lone Star tick (*Amblyomma americanum*) in the US. The reaction is characteristically delayed (3-6 hours) unlike typical protein-based food allergies.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. The vignette describes classic alpha-gal syndrome: delayed anaphylaxis (3-6 hours post-meal) to mammalian meat with elevated IgE to galactose-alpha-1,3-galactose. Key discriminating findings include: (1) delayed hypotension/syncope after dinner, (2) negative skin prick but positive intradermal tests to red meats, (3) normal tryptase (suggesting non-mast-cell-mediated baseline), (4) specific IgE to alpha-gal. The question asks for the sensitization vector. Amblyomma americanum (Lone Star tick, option B) is the established vector for alpha-gal syndrome in the United States, introducing alpha-gal through salivary proteins during blood meals. Ixodes scapularis (A) is associated with Lyme disease but not alpha-gal sensitization in North America. Dermacentor variabilis (C) is not a recognized alpha-gal vector. Aedes aegypti (D) and Ctenocephalides felis (E) are not implicated in alpha-gal syndrome. The keyed answer B is medically accurate and uniquely defensible based on established literature linking Lone Star tick bites to alpha-gal sensitization. No logical flaws or medical inaccuracies present. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The vignette describes classic alpha-gal syndrome: delayed anaphylaxis (3-6 hours post-meal) to mammalian meat with elevated IgE to galactose-alpha-1,3-galactose. Key discriminating findings include: (1) delayed hypotension/syncope after dinner, (2) negative skin prick but positive intradermal tests to red meats, (3) normal tryptase (suggesting non-mast-cell-mediated baseline), (4) specific IgE to alpha-gal. The question asks for the sensitization vector. Amblyomma americanum (Lone Star tick, option B) is the established vector for alpha-gal syndrome in the United States, introducing alpha-gal through salivary proteins during blood meals. Ixodes scapularis (A) is associated with Lyme disease but not alpha-gal sensitization in North America. Dermacentor variabilis (C) is not a recognized alpha-gal vector. Aedes aegypti (D) and Ctenocephalides felis (E) are not implicated in alpha-gal syndrome. The keyed answer B is medically accurate and uniquely defensible based on established literature linking Lone Star tick bites to alpha-gal sensitization. No logical flaws or medical inaccuracies present. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-007", "question": "A 78-year-old female is evaluated for progressive visual dysfunction. She reports difficulty reading and navigating her home, often bumping into doorframes. Her family notes she cannot reach for objects accurately (optic ataxia) and cannot describe the entire scene of a picture (simultanagnosia). Memory and language are relatively preserved. MRI shows predominant atrophy of the parietal and occipital lobes. What is the most likely underlying pathology?", "options": ["Lewy Body Disease", "Prion Disease (CJD)", "Alzheimer's Disease pathology (Amyloid plaques/Tau tangles)", "Frontotemporal Lobar Degeneration (TDP-43)", "Vascular Dementia"], "answer": "C", "answer_index": 2, "explanation": "This patient presents with Posterior Cortical Atrophy (PCA), also known as Benson's syndrome. The clinical hallmark is Balint's syndrome (simultanagnosia, optic ataxia, oculomotor apraxia) and Gerstmann's syndrome. Despite the atypical visual presentation, the underlying pathology in the vast majority (>80%) of PCA cases is Alzheimer's disease (amyloid plaques and neurofibrillary tangles).", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 78-year-old woman with progressive visual dysfunction, optic ataxia, simultanagnosia, preserved memory/language, and MRI showing parieto-occipital atrophy—classic features of Posterior Cortical Atrophy (PCA)/Benson's syndrome. Key discriminating findings: (1) visual-spatial deficits with optic ataxia and simultanagnosia (components of Balint's syndrome), (2) relative preservation of memory/language, (3) parieto-occipital predominant atrophy. PCA is a clinical syndrome with underlying pathology that is Alzheimer's disease (AD) in >80% of cases, making C the best answer. Alternative assessment: A (Lewy Body Disease) typically presents with visual hallucinations, parkinsonism, and fluctuating cognition—not the pattern here. B (CJD) would show rapid progression, myoclonus, and diffuse cortical involvement. D (FTLD-TDP43) causes behavioral/language syndromes, not posterior cortical syndromes. E (Vascular Dementia) would show stepwise decline and vascular lesions on MRI, not focal atrophy. The item is logically valid with a unique best answer matching the key. Medical accuracy is excellent—correctly identifies AD pathology as the predominant cause of PCA. No fix needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 78-year-old woman with progressive visual dysfunction, optic ataxia, simultanagnosia, preserved memory/language, and MRI showing parieto-occipital atrophy—classic features of Posterior Cortical Atrophy (PCA)/Benson's syndrome. Key discriminating findings: (1) visual-spatial deficits with optic ataxia and simultanagnosia (components of Balint's syndrome), (2) relative preservation of memory/language, (3) parieto-occipital predominant atrophy. PCA is a clinical syndrome with underlying pathology that is Alzheimer's disease (AD) in >80% of cases, making C the best answer. Alternative assessment: A (Lewy Body Disease) typically presents with visual hallucinations, parkinsonism, and fluctuating cognition—not the pattern here. B (CJD) would show rapid progression, myoclonus, and diffuse cortical involvement. D (FTLD-TDP43) causes behavioral/language syndromes, not posterior cortical syndromes. E (Vascular Dementia) would show stepwise decline and vascular lesions on MRI, not focal atrophy. The item is logically valid with a unique best answer matching the key. Medical accuracy is excellent—correctly identifies AD pathology as the predominant cause of PCA. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-008", "question": "A 28-year-old male with ulcerative colitis is admitted with jaundice and pruritus. MRCP shows multifocal strictures and dilations of the intrahepatic and extrahepatic bile ducts. IgG4 levels are 2x upper limit of normal. A liver biopsy shows periductal concentric fibrosis ('onion-skinning') without abundant plasma cells. A trial of high-dose corticosteroids results in no biochemical improvement. What is the diagnosis?", "options": ["IgG4-related Sclerosing Cholangitis", "Primary Sclerosing Cholangitis (PSC)", "Cholangiocarcinoma", "Secondary Sclerosing Cholangitis", "Autoimmune Hepatitis overlap syndrome"], "answer": "B", "answer_index": 1, "explanation": "This is classic Primary Sclerosing Cholangitis (PSC) associated with IBD. While IgG4 can be elevated in PSC (up to 15% of cases), the lack of response to steroids and the classic 'onion-skin' fibrosis distinguish it from IgG4-related Sclerosing Cholangitis (IgG4-SC). IgG4-SC typically responds dramatically to steroids and shows abundant IgG4+ plasma cells on biopsy.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 28-year-old male with ulcerative colitis presenting with jaundice, pruritus, and MRCP showing multifocal strictures/dilations of intra- and extrahepatic bile ducts—classic for PSC. Key discriminating findings: (1) strong IBD-PSC association (70-80% of PSC patients have IBD), (2) characteristic MRCP beading pattern, (3) onion-skin fibrosis on biopsy, (4) no steroid response, (5) absence of abundant plasma cells despite 2x elevated IgG4. The keyed answer (PSC) is defensible because elevated IgG4 occurs in ~9-15% of PSC cases and does not mandate IgG4-SC diagnosis. IgG4-SC (option A) is excluded by lack of steroid response and absence of abundant IgG4+ plasma cells—both hallmarks of IgG4-related disease. Cholangiocarcinoma (C) lacks supporting evidence (no dominant stricture/mass mentioned). Secondary sclerosing cholangitis (D) requires a known secondary cause not provided. Autoimmune hepatitis overlap (E) is unsupported by the clinical picture. The item correctly teaches that elevated IgG4 alone does not diagnose IgG4-SC; histologic confirmation and steroid responsiveness are required. Medical accuracy is excellent. No fix needed—the question appropriately tests differentiation of PSC from IgG4-SC mimics.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 28-year-old male with ulcerative colitis presenting with jaundice, pruritus, and MRCP showing multifocal strictures/dilations of intra- and extrahepatic bile ducts—classic for PSC. Key discriminating findings: (1) strong IBD-PSC association (70-80% of PSC patients have IBD), (2) characteristic MRCP beading pattern, (3) onion-skin fibrosis on biopsy, (4) no steroid response, (5) absence of abundant plasma cells despite 2x elevated IgG4. The keyed answer (PSC) is defensible because elevated IgG4 occurs in ~9-15% of PSC cases and does not mandate IgG4-SC diagnosis. IgG4-SC (option A) is excluded by lack of steroid response and absence of abundant IgG4+ plasma cells—both hallmarks of IgG4-related disease. Cholangiocarcinoma (C) lacks supporting evidence (no dominant stricture/mass mentioned). Secondary sclerosing cholangitis (D) requires a known secondary cause not provided. Autoimmune hepatitis overlap (E) is unsupported by the clinical picture. The item correctly teaches that elevated IgG4 alone does not diagnose IgG4-SC; histologic confirmation and steroid responsiveness are required. Medical accuracy is excellent. No fix needed—the question appropriately tests differentiation of PSC from IgG4-SC mimics.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-009", "question": "A 60-year-old female undergoes surveillance colonoscopy. A 15mm flat lesion is removed from the ascending colon. Pathology reveals a Sessile Serrated Lesion (SSL) with dysplasia. According to the 2020 US Multi-Society Task Force guidelines, when should her next surveillance colonoscopy be performed?", "options": ["1 year", "3 years", "5 years", "7 years", "10 years"], "answer": "B", "answer_index": 1, "explanation": "Sessile Serrated Lesions (SSLs) with dysplasia are considered high-risk precancerous lesions, equivalent in risk to high-risk adenomas (e.g., villous histology, high-grade dysplasia, or size >10mm). The recommended surveillance interval for an SSL with dysplasia (regardless of size) is 3 years. An SSL <10mm without dysplasia would be 5-10 years.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 60-year-old female with a 15mm flat SSL with dysplasia removed from the ascending colon during surveillance colonoscopy. Key discriminating findings: (1) SSL with dysplasia—a high-risk feature, (2) size 15mm (>10mm). Per 2020 US Multi-Society Task Force guidelines, SSLs with dysplasia are classified as high-risk lesions requiring 3-year surveillance, regardless of size. The keyed answer B (3 years) aligns with current guidelines. Alternative assessment: A (1 year) is too aggressive and reserved for piecemeal resection of large lesions or incomplete resection; C (5 years) applies to low-risk adenomas or SSLs <10mm without dysplasia; D (7 years) and E (10 years) are too long for any polyp with high-risk features. The item is medically accurate, citing appropriate guidelines. No logical flaws exist—the stem provides sufficient detail (lesion type, size, dysplasia presence) to determine a unique best answer. No contradictions, underspecification, or multiple defensible answers. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 60-year-old female with a 15mm flat SSL with dysplasia removed from the ascending colon during surveillance colonoscopy. Key discriminating findings: (1) SSL with dysplasia—a high-risk feature, (2) size 15mm (>10mm). Per 2020 US Multi-Society Task Force guidelines, SSLs with dysplasia are classified as high-risk lesions requiring 3-year surveillance, regardless of size. The keyed answer B (3 years) aligns with current guidelines. Alternative assessment: A (1 year) is too aggressive and reserved for piecemeal resection of large lesions or incomplete resection; C (5 years) applies to low-risk adenomas or SSLs <10mm without dysplasia; D (7 years) and E (10 years) are too long for any polyp with high-risk features. The item is medically accurate, citing appropriate guidelines. No logical flaws exist—the stem provides sufficient detail (lesion type, size, dysplasia presence) to determine a unique best answer. No contradictions, underspecification, or multiple defensible answers. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-010", "question": "A 55-year-old male with AL amyloidosis presents with extensive ecchymoses and a large hematoma after a minor venipuncture. Coagulation studies reveal a PT of 18s (Normal 11-13.5) and a PTT of 45s (Normal 25-35). Thrombin time is normal. Mixing studies correct both PT and PTT. Factor assays reveal Factor X activity of 8%. What is the mechanism of this deficiency?", "options": ["Autoantibody inhibition of Factor X", "Adsorption of Factor X onto amyloid fibrils", "Decreased hepatic synthesis of Factor X", "Urinary loss of Factor X due to nephrotic syndrome", "Consumption due to low-grade DIC"], "answer": "B", "answer_index": 1, "explanation": "Acquired Factor X deficiency is a rare but classic complication of AL amyloidosis (occurring in ~8-10% of patients). The mechanism is the adsorption (binding) of Factor X to the amyloid fibrils in the spleen and liver, removing it from circulation. It is not an inhibitor (antibody) or synthesis issue. Treatment often requires splenectomy or high-dose factor replacement to overwhelm the binding sites.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The vignette describes a 55-year-old male with AL amyloidosis presenting with bleeding diathesis, prolonged PT/PTT that correct on mixing studies, normal thrombin time, and severely reduced Factor X activity (8%). Key discriminating findings: (1) AL amyloidosis context, (2) mixing studies correct both PT/PTT—ruling out inhibitors, (3) isolated severe Factor X deficiency, (4) bleeding after minor trauma. The keyed answer (B: adsorption onto amyloid fibrils) is the classic mechanism for acquired Factor X deficiency in AL amyloidosis, where Factor X binds to amyloid deposits in spleen/liver, removing it from circulation. This is a well-documented phenomenon occurring in ~8-10% of AL amyloidosis patients. Alternative assessment: (A) ruled out by correcting mixing studies; (C) would affect multiple vitamin K-dependent factors and typically show abnormal thrombin time patterns; (D) nephrotic syndrome causes loss of antithrombin/protein S, not isolated Factor X; (E) DIC would show prolonged thrombin time, low fibrinogen, elevated D-dimer, and consumption of multiple factors. The item is medically accurate, logically sound, and tests knowledge of a classic hematologic complication. No fix needed.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 55-year-old male with AL amyloidosis presenting with bleeding diathesis, prolonged PT/PTT that correct on mixing studies, normal thrombin time, and severely reduced Factor X activity (8%). Key discriminating findings: (1) AL amyloidosis context, (2) mixing studies correct both PT/PTT—ruling out inhibitors, (3) isolated severe Factor X deficiency, (4) bleeding after minor trauma. The keyed answer (B: adsorption onto amyloid fibrils) is the classic mechanism for acquired Factor X deficiency in AL amyloidosis, where Factor X binds to amyloid deposits in spleen/liver, removing it from circulation. This is a well-documented phenomenon occurring in ~8-10% of AL amyloidosis patients. Alternative assessment: (A) ruled out by correcting mixing studies; (C) would affect multiple vitamin K-dependent factors and typically show abnormal thrombin time patterns; (D) nephrotic syndrome causes loss of antithrombin/protein S, not isolated Factor X; (E) DIC would show prolonged thrombin time, low fibrinogen, elevated D-dimer, and consumption of multiple factors. The item is medically accurate, logically sound, and tests knowledge of a classic hematologic complication. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-011", "question": "A 30-year-old female presents with recurrent sinopulmonary infections and splenomegaly. Labs show low IgG, low IgA, and variable IgM. She is diagnosed with Common Variable Immunodeficiency (CVID). Five years later, she develops progressive dyspnea. CT chest shows diffuse pulmonary nodules and mediastinal lymphadenopathy. Biopsy reveals non-necrotizing granulomas. Stains for fungi and mycobacteria are negative. What is the preferred initial treatment for this complication?", "options": ["Infliximab", "Rituximab and Azathioprine/Mycophenolate", "High-dose Intravenous Immunoglobulin (IVIG) alone", "Lung Transplantation", "Antituberculous therapy"], "answer": "B", "answer_index": 1, "explanation": "The patient has Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD), a distinct and serious complication of CVID. Unlike sarcoidosis, GLILD in CVID is driven by B-cell hyperplasia and T-cell dysregulation. The consensus treatment for progressive GLILD is combination immunosuppression, typically Rituximab (to deplete B cells) combined with an antimetabolite like Azathioprine or Mycophenolate. IVIG alone is insufficient for GLILD.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 30-year-old woman with established CVID (low IgG/IgA, recurrent sinopulmonary infections, splenomegaly) who develops progressive dyspnea 5 years later. CT shows diffuse pulmonary nodules and mediastinal lymphadenopathy; biopsy reveals non-necrotizing granulomas with negative infectious stains. This constellation is classic for Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD), a serious CVID complication. Key discriminating findings: (1) established CVID, (2) progressive pulmonary symptoms, (3) non-necrotizing granulomas, (4) negative infectious workup. The keyed answer (B: Rituximab + Azathioprine/Mycophenolate) aligns with current consensus for progressive GLILD, targeting B-cell hyperplasia and T-cell dysregulation. Alternative assessment: (A) Infliximab is second-line; (C) IVIG alone is insufficient for GLILD; (D) transplantation is reserved for end-stage disease; (E) antituberculous therapy is inappropriate given negative mycobacterial stains. The item is logically valid with a unique best answer matching the key. Medical accuracy is high, reflecting current GLILD management guidelines. No contradictions or underspecification present. Minimal fix: None needed; item is well-constructed and defensible.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 30-year-old woman with established CVID (low IgG/IgA, recurrent sinopulmonary infections, splenomegaly) who develops progressive dyspnea 5 years later. CT shows diffuse pulmonary nodules and mediastinal lymphadenopathy; biopsy reveals non-necrotizing granulomas with negative infectious stains. This constellation is classic for Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD), a serious CVID complication. Key discriminating findings: (1) established CVID, (2) progressive pulmonary symptoms, (3) non-necrotizing granulomas, (4) negative infectious workup. The keyed answer (B: Rituximab + Azathioprine/Mycophenolate) aligns with current consensus for progressive GLILD, targeting B-cell hyperplasia and T-cell dysregulation. Alternative assessment: (A) Infliximab is second-line; (C) IVIG alone is insufficient for GLILD; (D) transplantation is reserved for end-stage disease; (E) antituberculous therapy is inappropriate given negative mycobacterial stains. The item is logically valid with a unique best answer matching the key. Medical accuracy is high, reflecting current GLILD management guidelines. No contradictions or underspecification present. Minimal fix: None needed; item is well-constructed and defensible.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-012", "question": "A 62-year-old male with metastatic melanoma is treated with Ipilimumab and Nivolumab. Four weeks after the second cycle, he presents with fatigue, nausea, and hypotension. Labs show Sodium 130 mEq/L, Potassium 5.2 mEq/L, Glucose 65 mg/dL. TSH is 0.05 mIU/L (Low), Free T4 is 0.6 ng/dL (Low). ACTH is <5 pg/mL. MRI brain shows enlargement of the pituitary gland. What is the diagnosis?", "options": ["Primary Adrenal Insufficiency (Addison's)", "Immune Checkpoint Inhibitor-induced Hypophysitis", "Thyroid Storm", "Pituitary Metastasis", "Syndrome of Inappropriate ADH (SIADH)"], "answer": "B", "answer_index": 1, "explanation": "This is a classic presentation of hypophysitis (inflammation of the pituitary), a specific immune-related adverse event (irAE) strongly associated with CTLA-4 inhibitors (Ipilimumab). The key biochemical pattern is central hypothyroidism (Low TSH, Low T4) and central adrenal insufficiency (Low ACTH, Low Cortisol, hyponatremia/hyperkalemia). Primary adrenal insufficiency would have high ACTH. The MRI finding confirms pituitary inflammation.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a patient on dual checkpoint inhibitors (ipilimumab + nivolumab) presenting 4 weeks post-treatment with classic features of hypophysitis: fatigue, hypotension, hyponatremia, hyperkalemia, hypoglycemia, central hypothyroidism (low TSH, low free T4), central adrenal insufficiency (ACTH <5), and MRI-confirmed pituitary enlargement. Key discriminating findings: (1) CTLA-4 inhibitor exposure (ipilimumab strongly associated with hypophysitis), (2) low ACTH excluding primary adrenal insufficiency, (3) low TSH with low T4 indicating central hypothyroidism, (4) pituitary enlargement on MRI. Option B is uniquely defensible. Option A (Primary adrenal insufficiency) is excluded by low ACTH (would be elevated). Option C (Thyroid storm) contradicts low thyroid hormones. Option D (Pituitary metastasis) is possible but less likely given temporal relationship to immunotherapy and typical hypophysitis presentation. Option E (SIADH) doesn't explain the complete hormonal pattern, hyperkalemia, or pituitary enlargement. Medical accuracy: The biochemical pattern, timing, drug association, and MRI findings align perfectly with checkpoint inhibitor-induced hypophysitis per current oncology/endocrinology standards. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a patient on dual checkpoint inhibitors (ipilimumab + nivolumab) presenting 4 weeks post-treatment with classic features of hypophysitis: fatigue, hypotension, hyponatremia, hyperkalemia, hypoglycemia, central hypothyroidism (low TSH, low free T4), central adrenal insufficiency (ACTH <5), and MRI-confirmed pituitary enlargement. Key discriminating findings: (1) CTLA-4 inhibitor exposure (ipilimumab strongly associated with hypophysitis), (2) low ACTH excluding primary adrenal insufficiency, (3) low TSH with low T4 indicating central hypothyroidism, (4) pituitary enlargement on MRI. Option B is uniquely defensible. Option A (Primary adrenal insufficiency) is excluded by low ACTH (would be elevated). Option C (Thyroid storm) contradicts low thyroid hormones. Option D (Pituitary metastasis) is possible but less likely given temporal relationship to immunotherapy and typical hypophysitis presentation. Option E (SIADH) doesn't explain the complete hormonal pattern, hyperkalemia, or pituitary enlargement. Medical accuracy: The biochemical pattern, timing, drug association, and MRI findings align perfectly with checkpoint inhibitor-induced hypophysitis per current oncology/endocrinology standards. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-013", "question": "A 22-year-old female presents with recurrent episodes of abdominal pain and extremity swelling lasting 2-3 days. She has no urticaria during these episodes. Her C4 level is consistently low. C1-Inhibitor (C1-INH) quantitative level is 8 mg/dL (Normal 19-37) and C1-INH functional activity is 15% (Normal >68%). Which of the following is the most appropriate long-term prophylactic therapy?", "options": ["Antihistamines (Cetirizine)", "Omalizumab", "Danazol or Lanadelumab", "Systemic Corticosteroids", "Epinephrine auto-injector"], "answer": "C", "answer_index": 2, "explanation": "The patient has Hereditary Angioedema (HAE) Type 1 (low C1-INH level and function). HAE is bradykinin-mediated, not histamine-mediated; therefore, antihistamines, corticosteroids, and epinephrine are ineffective. Long-term prophylaxis is indicated for frequent attacks. Options include attenuated androgens (Danazol) or modern agents like Lanadelumab (kallikrein inhibitor) or Berotralstat. C1-INH replacement is also used.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 22-year-old female with recurrent abdominal pain and extremity swelling (2-3 days), no urticaria, consistently low C4, low C1-INH quantitative level (8 mg/dL), and low functional activity (15%). These findings definitively establish Hereditary Angioedema (HAE) Type 1. Key discriminating clues: (1) angioedema without urticaria excludes histamine-mediated processes; (2) low C4 with both quantitatively and functionally deficient C1-INH confirms HAE Type 1; (3) recurrent episodes warrant long-term prophylaxis. Option C (Danazol or Lanadelumab) is correct: attenuated androgens and kallikrein inhibitors are established prophylactic agents for HAE. Options A, B, D, E are all ineffective because HAE is bradykinin-mediated, not histamine/IgE-mediated; antihistamines, omalizumab, corticosteroids, and epinephrine do not address the underlying pathophysiology. No other option is defensible. Medical accuracy: fully consistent with current HAE management guidelines. The item correctly identifies that histamine-pathway therapies are ineffective and appropriately lists modern prophylactic options. No logical issues; stem provides sufficient detail for unique best answer. Minimal fix: none needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 22-year-old female with recurrent abdominal pain and extremity swelling (2-3 days), no urticaria, consistently low C4, low C1-INH quantitative level (8 mg/dL), and low functional activity (15%). These findings definitively establish Hereditary Angioedema (HAE) Type 1. Key discriminating clues: (1) angioedema without urticaria excludes histamine-mediated processes; (2) low C4 with both quantitatively and functionally deficient C1-INH confirms HAE Type 1; (3) recurrent episodes warrant long-term prophylaxis. Option C (Danazol or Lanadelumab) is correct: attenuated androgens and kallikrein inhibitors are established prophylactic agents for HAE. Options A, B, D, E are all ineffective because HAE is bradykinin-mediated, not histamine/IgE-mediated; antihistamines, omalizumab, corticosteroids, and epinephrine do not address the underlying pathophysiology. No other option is defensible. Medical accuracy: fully consistent with current HAE management guidelines. The item correctly identifies that histamine-pathway therapies are ineffective and appropriately lists modern prophylactic options. No logical issues; stem provides sufficient detail for unique best answer. Minimal fix: none needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-014", "question": "A 72-year-old male is evaluated for frequent falls. He reports that his legs feel 'heavy' and 'stuck to the floor' when he tries to start walking, but once moving, he can walk relatively well. He has urinary urgency and mild cognitive impairment. Physical exam reveals a broad-based, shuffling gait with difficulty lifting feet (magnetic gait). What is the most likely diagnosis?", "options": ["Parkinson's Disease", "Normal Pressure Hydrocephalus (NPH)", "Lumbar Spinal Stenosis", "Vascular Dementia", "Cerebellar Ataxia"], "answer": "B", "answer_index": 1, "explanation": "The clinical triad of gait disturbance, urinary incontinence (urgency), and dementia ('wobbly, wet, and wacky') suggests Normal Pressure Hydrocephalus (NPH). The specific description of a 'magnetic gait' (gait apraxia where feet appear stuck to the floor) is the hallmark and usually the earliest sign. It is distinguished from Parkinson's by the lack of resting tremor and the specific nature of the gait initiation failure.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict on keyed answer: Correct best. The vignette presents the classic NPH triad: (1) gait disturbance with magnetic/apraxic gait (feet stuck to floor, difficulty initiating walking), (2) urinary urgency (representing incontinence spectrum), and (3) mild cognitive impairment. The magnetic gait with initiation difficulty but relatively preserved walking once started is pathognomonic for NPH's gait apraxia. Key discriminating findings: 72-year-old with magnetic gait, urinary urgency, cognitive impairment, broad-based shuffling gait. Keyed answer (B-NPH) fits perfectly with the classic triad presentation. Alternative assessment: (A) Parkinson's typically shows resting tremor, rigidity, bradykinesia, and festinating gait rather than magnetic gait; no tremor mentioned here. (C) Lumbar stenosis causes neurogenic claudication relieved by sitting/flexion, not magnetic gait or cognitive/urinary symptoms. (D) Vascular dementia lacks the specific magnetic gait pattern and urinary urgency triad. (E) Cerebellar ataxia presents with wide-based ataxic gait, dysmetria, intention tremor, not magnetic gait or the NPH triad. No logical issues; stem provides sufficient discriminating features. Medical accuracy is excellent. Minimal fix: None needed; item is well-constructed and unambiguous.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The vignette presents the classic NPH triad: (1) gait disturbance with magnetic/apraxic gait (feet stuck to floor, difficulty initiating walking), (2) urinary urgency (representing incontinence spectrum), and (3) mild cognitive impairment. The magnetic gait with initiation difficulty but relatively preserved walking once started is pathognomonic for NPH's gait apraxia. Key discriminating findings: 72-year-old with magnetic gait, urinary urgency, cognitive impairment, broad-based shuffling gait. Keyed answer (B-NPH) fits perfectly with the classic triad presentation. Alternative assessment: (A) Parkinson's typically shows resting tremor, rigidity, bradykinesia, and festinating gait rather than magnetic gait; no tremor mentioned here. (C) Lumbar stenosis causes neurogenic claudication relieved by sitting/flexion, not magnetic gait or cognitive/urinary symptoms. (D) Vascular dementia lacks the specific magnetic gait pattern and urinary urgency triad. (E) Cerebellar ataxia presents with wide-based ataxic gait, dysmetria, intention tremor, not magnetic gait or the NPH triad. No logical issues; stem provides sufficient discriminating features. Medical accuracy is excellent. Minimal fix: None needed; item is well-constructed and unambiguous.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]